Most researchers searching for CJC-1295 in Pala soon discover that local retail options are virtually absent. What this means for Pala researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those evaluation tools are accessible to anyone. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what Pala researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
The Science Behind CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Pala studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Sourcing Research-Grade CJC-1295
Quality CJC-1295 sourcing begins with a useful first test: does this vendor make batch-matched COAs available before purchase? Suppliers that publish proactively are demonstrating research-grade standards. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from bacterial cell wall components can trigger serious immune reactions even at trace quantities. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, unclear production details, no community presence, and COAs that do not include endotoxin results. Bacteriostatic water is the correct reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to 4 weeks when kept refrigerated.
Order CJC-1295 — ships to Pala
COA-verified · International tracking · Research grade
All use of CJC-1295 in Pala or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should follow research laboratory protocols. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution kept at 2-8°C refrigerated and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. Quality CJC-1295 sourcing is not separable from research safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that rigorous vendor evaluation eliminates. Researchers using CJC-1295 alongside other research compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
